DaVita Inc.
DVA · Healthcare
$176.14
Loading chart…
News
Latest headlines for this stock
Can Fresenius Medical's 5008X Rollout Drive the Next Growth Phase?
Fresenius Medical Care is scaling up its 5008X CAREsystem rollout, converting 227 U.S. clinics to the new technology by July 2026, representing 10% of its machine base. The company has performed over 600,000 treatments including 100,000+ high-volume hemodiafiltration treatments, showing clinical promise with 40% fewer muscle cramps. However, near-term headwinds include weak U.S. treatment volume growth (-0.9%), TDAPA reimbursement pressure (€50 million drag expected), and significant rollout implementation costs.
Zacks Industry Outlook Highlights DaVita, LifeStance Health, Option Care Health, and Aveanna Healthcare
The Outpatient & Home Healthcare industry is experiencing rapid growth driven by digital transformation, an aging population, and cost-effectiveness advantages. The industry has a Zacks Industry Rank #52 (top 21%) with a forward P/E of 19.1X. Four key stocks are highlighted: LifeStance Health (Rank #2) with 19.7% revenue growth, Option Care Health (Rank #2) with 1.9% revenue growth, Aveanna Healthcare (Rank #2) with 10.6% revenue growth, and DaVita (Rank #3) with 4.7% revenue growth.
Warren Buffett and Greg Abel Quietly Hold a Bigger Percentage of This Company Than Any Other in Berkshire's Portfolio (Hint: It's Not Apple or American Express)
Berkshire Hathaway holds nearly 45% of DaVita, a kidney dialysis healthcare company, representing its largest proportional equity stake—larger than Apple or American Express. Despite recent modest sell-offs in 2025, DaVita has surged over 56% year-to-date, driven by strong Q1 earnings that beat analyst expectations. The company offers consistent profitability, revenue growth, and an attractive forward P/E ratio of just over 12.